Thursday, September 13

16:30 Registrations

17:00-17:15 Welcome and Introduction  
\textbf{Pantelis Sarafidis, Aikaterini Papagianni}

17:15-18:00 Introductory Lecture

18:00-20:00 Session 1

\textbf{Chairs: Ioannis N. Boletis, Stylianos Panagoutsos}

- \textbf{Raymond Vanholder}  
  Metabolomics approach to cardiovascular risk in CKD

- \textbf{Jolanta Malyszko}  
  Atrial Fibrillation in CKD: an unduring, scarcely focused problem

- \textbf{Aikaterini Papagianni}  
  An update on the role of FGF-23 and Klotho axis in cardiovascular disease

- \textbf{Mariann e Verhaar}  
  Regenerative nephrology: a 2018 update

Friday, September 14

09:00-11:00 Session 2

\textbf{Chairs: Ioannis Stefanidis, Vassilios Liakopoulos}

- \textbf{Mario Cozzolino}  
  Vitamin D rehabilitated for vascular health

- \textbf{Etienne Cavalier}  
  Biomarkers from bone...and beyond!

- \textbf{Sandro Mazzaferro}  
  Inflammation at the crossroad of MBD and cardiovascular disease

- \textbf{Ziad A. Massy}  
  Middle-molecule uremic toxins and outcomes in CKD
11:00-11:30 Coffee-Break

11:30-13:30 Session 3

Chairs: Ploumis Passadakis, Asterios Karagiannis

- Carmine Zoccali Neuro-immune links and cardiovascular and renal outcomes in CKD
- Andrzej Więcek Renal denervation – a chance to slow the CKD progression?
- Apostolos Tsapas Cardiovascular and renal effects of SGLT-2 inhibitors and GLP-1 agonists: an update based on upcoming ADA/EASD guidelines
- Pantelis Sarafidis Ambulatory BP, pulse wave analysis and BP variability: potential value in dialysis

13:30-14:30 Lunch Break

14:30-16:30 Session 4

Chairs: Anastasios Lazaridis, Dimitrios Vlachakos,

- Francesca Mallamaci Sleeping disordered breathing in CKD: relevance for cardiovascular and renal outcomes
- Charles Ferro Myocardial fibrosis in CKD - from clinic to laboratory and back to the clinic
- Patrick Mark Stroke and vascular cognitive decline in CKD- what are the targets for intervention?
- Mehmet Kanbay An update about uric acid in CKD: What should we know and do?

16:30-16:45 Coffee-Break

16:45-18:30 Session 5

Chairs: Pantelis Zebekakis, Elias Balaskas

- Jose Valdivielso Atherosclerosis in CKD: is it really different from the general population?
- Robert Ekart Obesity in patients with CKD: an unappreciated epidemic?
- Michael Doumas Sexual dysfunction in CKD: a circulatory defect or more?

Saturday, September 15
09:00-11:00 Session 6

Chairs: Dimitrios Goumenos, Theophonis Apostolou,

- Joao Frazão The Bone-Vessel axis
- Marc Vervloet Vascular phosphate toxicity revisited
- Mariano Rodriguez The role of dietary fat in vascular calcification
- Gerard London Parathyroid hormone as a cardiovascular risk factor in CKD: a reassessment in 2018

11:00-11:30 Coffee-Break

11:30-13:30 Session 7

Chairs: Elias Thodis, Stella Douma

- Costas Tsioufis Update on pharmaceutic and interventional treatment of resistant hypertension
- Pablo Ureña-Torres Effects of antihypertensive treatment on the skeleton
- Alberto Ortiz Sex differences in CKD incidence and outcomes: beyond sex hormones?
- Danilo Fliser RAAS blockade and hyperkalemia - a cause of concern or not?

13:30-13:45 Conclusions and Farewell Pantelis Sarafidis, Dimitrios Goumenos